Episode
AliveAndKickn Podcast - Dr Matthias Kloor
- Podcast
- AliveandKick'n the podcast
- Published
- Mar 17, 2025
- Duration seconds
- 2673
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/aliveandkick-n-the-podcast-1330226/episodes/aliveandkickn-podcast-dr-matthias-kloor/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/aliveandkick-n-the-podcast-1330226/aliveandkickn-podcast-dr-matthias-kloor.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
I sit down with Dr. Matthias Kloor, Acting Medical Director Applied Tumor Biology at Heidelberg University. We discuss the thought process followed by the hurdles faced in trying to get a Lynch Syndrome vaccine, through the phases, to potentially the proverbial bedside. We discussed collaboration with the NCI in bringing this and other projects to market. We also talk about the European Hereditary Tumor Group, whose conference this year is also in Heidelberg. EHTG is a great group, one that has embraced the advocacy community, similar to CGAIGC and InSIGHT.